The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Much Larger Will The Compounding Chemotherapy Market Become By 2030 Compared To 2026?
The compounding chemotherapy market has demonstrated strong growth in recent years. It is projected to expand from $6.11 billion in 2025 to $6.49 billion in 2026, at a compound annual growth rate (CAGR) of 6.2%. The historical increase can be attributed to factors like the limited accessibility of compounding technologies, the rising incidence of cancer, the reliance on hospital-based compounding services, heightened awareness regarding cytotoxic drug safety, and the prevalent adoption of manual preparation methods.
The compounding chemotherapy market size is projected to experience robust expansion in the coming years, reaching $8.2 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. This anticipated growth can be linked to several factors, including the emergence of automated and robotic compounding systems, the spread of homecare chemotherapy services, increased funding for sterile pharmacy infrastructure, stricter regulatory adherence for individualized medical treatments, and the rise of targeted therapies and immunomodulatory agents. Significant developments expected during this period involve a greater embrace of personalized chemotherapy formulations, the incorporation of robotic compounding systems, an increase in compounding services offered in homecare and specialized clinics, a heightened emphasis on maintaining sterile and contamination-free environments, and an escalating need for supportive care drug compounding.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25724&type=smp
Which Growth Factors Are Strengthening The Compounding Chemotherapy Market Landscape?
The rising frequency of cancer cases is predicted to drive the expansion of the compounding chemotherapy market moving forward. Cancer refers to a group of illnesses marked by the unregulated proliferation and spread of abnormal cells throughout the body. The increasing incidence of cancer is primarily attributed to unhealthy habits, such as poor eating, lack of exercise, smoking, excessive alcohol consumption, and extended exposure to environmental contaminants, which significantly heighten the risk of developing various forms of cancer. Compounding chemotherapy supports cancer treatment by enabling customized drug formulations tailored to individual patient needs, thereby enhancing effectiveness and minimizing adverse reactions. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, indicated that there were 354,820 new cancer diagnoses in 2023, averaging 972 per day, which represents an increase of 8,605 compared to 2022. Therefore, the growing occurrence of cancer cases fuels the growth of the compounding chemotherapy market.
How Does Segment Analysis Break Down The Compounding Chemotherapy Market Structure?
The compounding chemotherapy market covered in this report is segmented –
1) By Drug Type: Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs
2) By Route Of Administration: Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal
3) By Technology: With Robotic Arms, Without Robotic Arms
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Compounding Setting: Hospital Compounding, Compounding Pharmacies, Specialty Clinics, Homecare Settings
Subsegments:
1) By Cytotoxic Drugs: Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, Topoisomerase Inhibitors
2) By Hormonal Agents: Estrogen Antagonists, Androgen Deprivation Therapy Agents, Aromatase Inhibitors, Progestins, Gonadotropin-Releasing Hormone Agonists
3) By Immunomodulatory Agents: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Interleukins, Cytokines, Immune System Activators
4) By Targeted Therapies: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Poly Polymerase Inhibitors
5) By Supportive Care Drugs: Antiemetics, Erythropoiesis-Stimulating Agents, Bone-Modifying Agents, Pain Management Drugs
What Trends Are Affecting The Compounding Chemotherapy Market Dynamics?
Leading companies active in the compounding chemotherapy market are concentrating on creating innovative solutions, like robotic chemotherapy automation systems, to boost precision, security, and efficiency in customizing cancer treatment preparation. Robotic chemotherapy automation systems represent sophisticated machinery built to accurately and safely produce personalized chemotherapy doses through the automation of the compounding procedure, thereby lessening human error and contamination dangers. For example, in February 2024, Simplivia Healthcare Ltd., an Israel-based healthcare technology company, unveiled Smart Compounders Advanced Systems to automate and streamline the preparation of cytotoxic (chemotherapy) drugs. These systems manage the compounding of cytostatics and antibodies, processing 20 to 40 preparations per hour, and include automatic gravimetric verification and documentation to ensure high accuracy. They substantially decrease pharmacy staff’s exposure to hazardous materials and are engineered to integrate smoothly into existing laminar airflow (LAF) cabinets or isolators without needing any modifications.
Who Are The Businesses Driving Activity In The Compounding Chemotherapy Market?
Major companies operating in the compounding chemotherapy market are Baxter International Inc., Fresenius Kabi AG, Option Care Health Inc., ICU Medical Inc., Fagron NV, BioScrip Inc., B. Braun Melsungen AG, Medisca Pharmaceutique Inc., Central Admixture Pharmacy Services Inc., Icon Group Holdings Pty Ltd, Avella Specialty Pharmacy, McGuff Compounding Pharmacy Services Inc., Epicur Pharma LLC, PharMEDium Services LLC.
Access The Complete Compounding Chemotherapy Market Report:
https://www.thebusinessresearchcompany.com/report/compounding-chemotherapy-global-market-report
What Is The Largest Regional Market In The Compounding Chemotherapy Market?
North America was the largest region in the compounding chemotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the compounding chemotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Compounding Chemotherapy Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=25724&type=smp
Browse Through More Reports Similar to the Global Compounding Chemotherapy Market 2026, By The Business Research Company
Chemotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report
Oncology Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Oncology Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model